Prominent Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Trend for 2025: Innovations In SGLT2 Inhibitors For Enhanced Diabetes And Heart Failure Management

What Are the Projected Growth and Market Size Trends for the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?
In the past few years, the market size for sodium glucose cotransporter 2 (SGLT2) inhibitors has seen a robust growth. From $10.17 billion in 2024, it is projected to expand to $11.07 billion in 2025, experiencing an 8.8% compound annual growth rate (CAGR). This upward trend during the historical time frame is owing to successful early-stage clinical trials, a rise in regulatory green lights, a surge in the identification rate of diabetes, and the increasing demand for pioneering diabetes therapies.

The market for sodium glucose cotransporter 2 (SGLT2) inhibitors is predicted to experience significant expansion in the approaching years, with an anticipated worth of $15.4 billion in 2029, achieved through a compound annual growth rate (CAGR) of 8.6%. The forecast period's growth is linked to factors such as the escalating prevalence of diabetes, rising obesity levels, heightened awareness about diabetes care, and the enlarged use of these inhibitors in treating heart and kidney diseases. Noteworthy trends for the forecast period incorporate the amalgamation of combination therapies, the introduction of personalised medicine, advancements in technology, and the conventional drug development process.

What Is Driving the Growth Trajectory of the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?
With the rise in incidences of diabetes, it is predicted that the sodium glucose cotransporter 2 (SGLT2) inhibitor market will see significant growth. Diabetes, a suite of metabolic disorders defined by elevated blood sugar levels due to either insufficient insulin production, impaired insulin functionality or both, has been on the upswing owing to factors such as urbanization, stress, environmental pollution and limited access to healthcare services. SGLT2 inhibitors, which function by impeding glucose reabsorption in the kidneys thereby helping to lower blood glucose levels by excreting it through urine, are being extensively used in treating diabetes. These inhibitors also have cardiovascular and renal advantages and hence are considered crucial in managing diabetes and its related complications. For example, data from the Australian Bureau of Statistics in December 2023 shows that in 2022, around 5.3% or roughly 1.3 million Australians had been diagnosed with diabetes, with similar rates among males (5.8%) and females (4.9%). The frequency of diabetes has been on a steady incline, notably among older age groups, with 18.7% of people aged 75 and above having this condition. The most widespread form is Type 2 diabetes, comprising 87.6% of the total cases. Additional risk factors include being an immigrant, residing in less affluent communities and having a disability. Consequently, the surge in diabetes prevalence is fuelling the expansion of the sodium glucose cotransporter 2 (SGLT2) inhibitor market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18473&type=smp

Which Leading Companies Are Shaping the Growth of the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?
Major companies operating in the sodium glucose cotransporter 2 (SGLT2) inhibitors market are Pfizer Inc., Johnson & Johnson Inc., Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, Boehringer Ingelheim International GmBH, Astellas Pharma Inc, Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd, Sumitomo Dainippon Pharma Co. Ltd., Taisho Pharmaceutical Holdings Co. Ltd., Lupin Limited, Glenmark pharmaceuticals, Torrent Pharmaceuticals Ltd, Mankind Pharma Ltd, Kissei Pharmaceutical Co. Ltd., Patsnap Synapse, Kotobuki Pharmaceutical Co Ltd.

What Are the Major Trends Shaping the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?
Prominent entities present in the sodium glucose cotransporter 2 (SGLT2) inhibitor market are making strides towards the development of dual inhibitor therapeutic solutions, in an effort to ameliorate patient outcomes and better regulate blood glucose levels. These therapeutic solutions involving dual inhibitors simultaneously target sodium-glucose cotransporters (SGLT1 and SGLT2) to optimize the efficacy in treating conditions such as diabetes and heart failure. As an example, in May 2023, the US-based biopharmaceutical corporation, Lexicon Pharmaceuticals Inc., was granted approval from the Food and Drug Administration (FDA) for the heart failure treatment, sotagliflozin. This first-class dual inhibitor of sodium-glucose cotransporters 1 and 2, which is administered once daily, is aimed to decrease occurrences of heart failure hospitalizations, cardiovascular death, and urgent heart failure visits in adults who have heart failure, type 2 diabetes, chronic kidney maladies and other cardiovascular risk factors. The product has the added advantage of diminishing renal glucose and sodium reabsorption, which then results in a decrease in preload and afterload and a lessened sympathetic activity.

What Are the Key Segments of the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?
The sodium glucose cotransporter 2 (SGLT2) inhibitors market covered in this report is segmented -

1) By Type: Invokana, Jardiance, Farxiga Or Forxiga, Suglat
2) By Route Of Administration: Oral Route, Other Route Of Administration
3) By End User: Hospitals, Homecare Settings, Clinics

Subsegments:
1) By Invokana: Generic Invokana (Canagliflozin), Branded Invokana
2) By Jardiance: Generic Jardiance (Empagliflozin), Branded Jardiance
3) By Farxiga Or Forxiga: Generic Farxiga (Dapagliflozin), Branded Farxiga
4) By Suglat: Suglat (Sotagliflozin) For Diabetes, Suglat (Sotagliflozin) For Heart Failure

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/sodium-glucose-cotransporter-2-sglt2-inhibitors-global-market-report

Which Region Dominates the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?
North America was the largest region in the sodium glucose cotransporter 2 (SGLT2) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sodium glucose cotransporter 2 (SGLT2) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Is Covered In The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Global Market Report?

- Market Size Analysis: Analyze the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18473

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.